Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- MHLW to Expand MID-NET and Coordinate with Other Databases and Registries to Improve Safety Measures: Official
August 27, 2018
- It’s Too Early to Introduce Incentives for Biosimilar Use: MHLW Official
August 27, 2018
- MHLW to Issue Optimal Use Guidelines for Imfinzi, Might Make Changes on Latest Data
August 23, 2018
- MHLW Orders Label Revisions for 7 Flu Drugs Including Tamiflu
August 23, 2018
- Chuikyo Discusses ICER Evaluations for Drugs with Multiple Indications
August 23, 2018
- Chuikyo to Allow “Ranged” ICER Values in Cost-Effective Assessment
August 23, 2018
- Chuikyo Members Call for More Info Disclosure for CEA Scheme
August 23, 2018
- Chuikyo OKs Pricing of Entyvio, Imfinzi, Gazyva and More; Listing on Aug. 29
August 22, 2018
- MHLW OKs Opdivo’s Add’l Indications and Flat Dose, 1st-Line Tagrisso Use and More
August 22, 2018
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
- Impasse Continues over Mumps Vaccine Inclusion in Public Immunization Programs
August 20, 2018
- MHLW Panel to Review Kyorin’s OAB Drug Vibegron and More on Aug. 30
August 17, 2018
- MHLW Revving Up Biosimilar Drive with Educational Workshop for Healthcare Pros
August 17, 2018
- Astellas AML Drug, Pfizer’s Lorlatinib Up for MHLW Panel Review on Aug. 29
August 16, 2018
- Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
- Collaboration Research Project between Ministries Aims to Develop AI by FY2021 for Drug Discovery for Lung Cancer, IPF
August 16, 2018
- EFPIA Japan Proposes Establishing Organization Formed by Multiple Companies for Blood Collection Operation
August 10, 2018
- No Applications Yet for “Certificated Data Operator” under Medical Infrastructure Law; Govt Hoping for First Certification in FY2018
August 9, 2018
- First Drug Maker Applies to Use MID-NET: PMDA
August 7, 2018
- MHLW Panel Backs Lilly’s Ibrance Contender Abemaciclib for Breast Cancer
August 6, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…